Data on Higher Dose of Copaxone and Data Showing Copaxone is Most
Cost Effective
Data Published in Neurology Showed That Higher Dose of Copaxone
Increased Efficacy in Relapsing-remitting Multiple Sclerosis
(RRMS)
Doubled Dose of
COPAXONE Maintained Proven Safety Profile and
Further Reduced Relapses and Lesions
JERUSALEM, Israel, April 17, 2007 – A 9-month, rando...
Treatment with Copaxone Plus Minocycline Showed Substantial
Reduction of Disease Activity in Patients with Active
Relapsing-Remitting Multiple Sclerosis
Treatment with
Copaxone Plus Minocycline Showed Substantial
Reduction of Disease Activity in Patients with Active
Relapsing-Remitting Multiple Sclerosis
Combination Treatment With Antibiotic Further Reduced Brain
Lesions and Was Well Tolerated
KANSAS CITY, Mo, May 4, 2007 - New data from a ran...
Treatment with Copaxone Plus Minocycline Showed Substantial
Reduction of Disease Activity in Patients with Active
Relapsing-Remitting Multiple Sclerosis
KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data from a
randomized, double-blind study showed that a combination of
COPAXONE(R) (glatiramer acetate injection) along with the oral
antibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesions
of the brain by 63 percent (p=0.08) in pati...
Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
... drug-treatment rate in newly diagnosed patients.
"Surveyed neurologists' responses suggest that Biogen Idec's Avonex is more at-risk than Teva's
copaxone of losing share upon the launch of either oral cladribine or fingolimod, as more physicians cite Avonex as having potential for being replaced by eith...
Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
...o be more efficacious and more convenient (weekly versus daily
dosing) than
copaxone for the treatment of multiple sclerosis. PI-2301
works through immune modul...and, in preclinical studies, has shown to be more potent and
effective than
copaxone in treating disease models for multiple sclerosis.
PI-2301 has also shown e...
Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
...301 has been optimized using Peptimmune's novel platform peptide
chemistry and, in preclinical studies, has shown to be more potent and
effective than
copaxone in treating disease models for multiple sclerosis.
PI-2301 has also shown efficacy in preclinical models of autoimmune
diseases where immune modulatio...
Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
...along with the significant improvements on bioavailability and
pharmacodynamic effects with PI-2301, provide further evidence that PI-2301
may replace
copaxone as first-line therapy in relapsing remitting multiple
sclerosis," stated Thomas P. Mathers, President and CEO of Peptimmune. "We
have designed PI-2301...